Evaluation of Perylene Bisimide-Based Ru-Ii and Ir-Iii Complexes As Photosensitizers for Photodynamic Therapy

Cristina Mari,Huaiyi Huang,Riccardo Rubbiani,Marcus Schulze,Frank Wuerthner,Hui Chao,Gilles Gasser
DOI: https://doi.org/10.1002/ejic.201600516
IF: 2.551
2016-01-01
European Journal of Inorganic Chemistry
Abstract:The synergistic action of a photosensitizer (PS), light, and oxygen is exploited in photodynamic therapy (PDT) to kill cancer cells with reduced side-effects compared with traditional chemotherapeutic treatments. In this regard, new PSs are still necessary to improve the efficacy and the outcomes of this medical technique. Over the past years, metal complexes have attracted interest as alternatives to traditional porphyrin and phthalocyanin-based PSs because of their tunable and thus tailor-made photophysical properties. Among others, Ru-II and Ir-III derivatives have shown promising results. Here, we report on the investigation of [Ru(bpy)(2)(ab-PBI)][PF6](2) (1) and [Cp* Ir-(ab-PBI)Cl]PF6 (2), where bpy = 2,2'-bipyridine, ab-PBI = azabenz-annulated perylene bisimide, and Cp* = pentamethyl-cyclopentadiene, as potential PDT PSs. These compounds display good photostability, as well as interesting singlet oxygen generation upon irradiation at 420 nm (in particular 2). Their biological activity was evaluated on four cell lines and, although the cytotoxicity of 1 did not improve significantly upon light irradiation, 2, which localizes in mitochondria of HeLa cells as indicated by ICP-MS measurements, reached nanomolar IC50 values on all the cell lines tested when activated with 420 nm light in low doses (9.27 J cm(-2)).
What problem does this paper attempt to address?